

NYSE: SMI HKSE: 981

**SMIC Investor Relations** 

April 2014

#### **Safe Harbor Statements**

#### **Under the Private Securities Litigation Reform Act of 1995**

This presentation contains, in addition to historical information, "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements under Second Quarter 2014 Guidance", statements regarding future 2014 capital expenditures are based on SMIC's current assumptions, expectations and projections about future events. SMIC uses words like "believe", "anticipate", "intend", "estimate", "expect", "project", "target", "plan" and similar expressions to identify forward-looking statements, although not all forward-looking statements contain these words. These forward-looking statements involve significant risks, both known and unknown, uncertainties and other factors that may cause SMIC's actual performance, financial condition or results of operations to be materially different from those suggested by the forward-looking statements including, among others, risks associated with the global economic slowdown, orders or judgments from pending litigation and financial stability in end markets.

Investors should consider the information contained in SMIC's filings with the U.S. Securities and Exchange Commission (SEC), including its annual report on 20-F filed with the SEC on April 14, 2014, especially the consolidated financial statements, and such other documents that SMIC may file with the SEC or The Hong Kong Stock Exchange Limited ("SEHK") from time to time, including current reports on Form 6-K. Other unknown or unpredictable factors also could have material adverse effects on SMIC's future results, performance or achievements. In light of these risks, uncertainties, assumptions and factors, the forward-looking events discussed in this presentation may not occur. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date stated, or if no date is stated, as of the date of this presentation. Except as may be required by law, SMIC undertakes no obligation and does not intend to update any forward-looking statement, whether as a result of new information, future events or otherwise.

To supplement SMIC's consolidated financial results presented in accordance with IFRS, SMIC uses in this presentation measures of operating results that are adjusted to exclude wafer shipments from Wuhan Xinxin Semiconductor Manufacturing Corporation ("Wuhan Xinxin"), which SMIC began gradually phasing out in 3Q13. There were no wETID EMC /P &MCID 24k &MCID 244 &BDC BT1 0 0 1 308.45 359.22 Tm[ )]TET EMC /P



### **1Q14 Financial Highlights**

- Revenue was \$451.1M
  - decreased 8.3% QoQ
  - decreased 6.7% QoQ compared to non-GAAP\* revenue
- Gross margin was 21.3%
  - compared to 18.9% in 4Q13
  - compared to 19.2% non-GAAP\* gross margin in 4Q13
- Profit from operations was \$29.6 M
  - compared to \$8.1 M in 4Q13
- Profit attributable to SMIC was \$20.3 M
  - compared to \$14.7 M in 4Q13
  - eighth consecutive quarter of positive net profit
- Total debt to equity ratio was 38.5%
  - compared to 45.2% in 4Q13

**Note:** Non-GAAP revenue and gross margin refers to revenue and gross margin excluding wafer shipments from Wuhan Xinxin.






#### **Income Statement Highlights**

| (US\$ thousands)                 | 1Q14      | 4Q13     | QoQ    | 1Q13     | YoY      |
|----------------------------------|-----------|----------|--------|----------|----------|
| Total Revenue                    | 451,083   | 491,797  | -8.3%  | 501,609  | -10.1%   |
| Gross Profit                     | 96,118    | 92,939   | 3.4%   | 98,288   | -2.2%    |
| Gross Margin                     | 21.3%     | 18.9%    | -      | 19.6%    | -        |
| Operating Expenses               | (66,533)  | (84,840) | -21.6% | (46,967) | 41.7%    |
| Research & Development           | (36,653)  | (46,256) | -20.8% | (24,758) | 48.0%    |
| General & Administrative         | (23, 193) | (36,610) | -36.6% | (34,203) | -32.2%   |
| Selling & Marketing              | (9,708)   | (8,385)  | 15.8%  | (8,254)  | 17.6%    |
| Other operating income (expense) | 3,021     | 6,411    | -52.9% | 20,248   | -85.1%   |
| Profit from operations           | 29,585    | 8,099    | 265.3% | 51,321   | -42.4%   |
| Other income (expense), net      | (9,189)   | 7,756    | -      | (8,273)  | 11.1%    |
| Income tax (expenses) benefit    | (1,454)   | (170)    | 755.3% | (2,536)  | -42.7%   |
| Profit attributable to SMIC      | 20,261    | 14,681   | 38.0%  | 40,604   | -50.1%   |
| Non-controlling Interests        | (1,319)   | 1,004    | -      | (92)     | 1,333.7% |
| Earnings per ADS                 | 0.03      | 0.02     | -      | 0.06     | -        |

- R&D expenses decreased mainly due to an increase in funding of R&D contracts from the government, which was \$11.7 million in 1Q14, compared to \$4.7 million in 4Q13.
- General and administrative expenses decreased mainly due to 1) a decrease of bad debt expense recognized and 2) a
  decrease in accrued employee bonus, and 3) a decrease of government tax surcharges in 1Q14.
- Other operating income decreased mainly due to the gain arising from the deconsolidation of Brite due to loss of control recorded in 4Q13.

# Non-GAAP Revenue and Revenue from Wuhan Xinxin



3Q13

Revenue from Wuhan XinXin

4Q13

There will be no wafer shipments from Wuhan Xinxin from 1Q14 onwards.

2Q13

■ Non-GAAP Revenue

1Q13

1Q14



## **Balance Sheet Highlights**

| (US\$ thousands)            | For the three months e | nded         |  |
|-----------------------------|------------------------|--------------|--|
|                             | Mar 31, 2014           | Dec 31, 2013 |  |
| Cash and bank balances      | 437,575                | 462,483      |  |
| Restricted Cash             | 120,338                | 147,625      |  |
| Other financial assets      | 178,383                | 240,311      |  |
| Trade and other receivables | 361,536                | 379,361      |  |
| Inventories                 | 294,375                | 286,251      |  |
| Other Assets                | 2,974,095              | 3,007,361    |  |
| Total Assets                | 4,366,302              | 4,523,392    |  |
| Short-term borrowings       | 313,191                | 390,547      |  |
| Long-term borrowings        | 512,075                | 600,975      |  |
| Convertible bonds           | 182,149                | 180,563      |  |
| Total Debt                  | 1,007,415              | 1,172,085    |  |
| Total Liabilities           | 1,748,604              | 1,930,210    |  |
| Total Equity                | 2,617,698              | 2,593,182    |  |
| Debt/Equity Ratio*          | 38.5%                  | 45.2%        |  |

<sup>\*</sup> Calculated based on (Total Debt) / (Total Equity)





cash and bank balances

Cash and bank balances,


end of period

#### **Cash Flow Highlights**

| (US\$ thousands)                             | For the three months ended |              |  |  |
|--|----------------------------|--------------|--|--|
|  | Mar 31, 2014               | Dec 31, 2013 |  |  |
| Cash and bank balances, beginning of period  | 462,483                    | 473,507      |  |  |
| Net cash from operating activities           | 169,378                    | 205,437      |  |  |
| Net cash used in investing activities        | (24,912)                   | (269,147)    |  |  |
| Net cash (used in) from financing activities | (168,382)                  | 52,749       |  |  |
| Net increase (decrease) in                   | (24,908)                   | (11,024)     |  |  |

437,575


## **Cash Flow from Operations**






462,483

## **Total Revenue Breakdown by Applications**




1Q 14 vs. 4Q 13




## **Total Revenue Breakdown by Geography**











#### China




#### **Eurasia**






## Wafer Revenue Breakdown by Technology




#### 1Q 14 vs. 4Q 13





### Capacity, Utilization and Shipment





(1) Capacity utilization rate is reported based on total equivalent wafers out divided by estimated total quarterly capacity





|                                 | 2Q 2014 Guidance                        |           |              |
|---------------------------------|---|-----------|--------------|
| Revenue                         | +12% to +15 %<br>\$505 to \$518 million |           |              |
| Gross Margin                    | 22% to 24%                              |           | 1,000        |
| Non-GAAP Operating Expenses (1) | \$89 to \$93 million                    | <br>Found | dry Operatio |

- (1) Exclude the effect of employee bonus accrual, funding of R&D contracts from the government and gain from the disposal of living quarters.
- (2) The planned 2014 capital expenditures for our foundry operations are raised to approximately \$1 billion from the previous \$880 million, of which the increase will be for the acquisition of equipment for our Shenzhen 8-inch fab. Around \$570 million will be for





# **Appendix**



#### **1Q14 Results Vs Guidance**

|                                 | 1Q 2014 Guidance     | 1Q 2014 Results |  |  |
|---------------------------------|----------------------|-----------------|--|--|
| Revenue (1)                     | -9% to -5%           | -6.7%           |  |  |
| Gross Margin                    | 16% to 19%           | 21.3%           |  |  |
| Non-GAAP Operating Expenses (2) | \$88 to \$92 million | \$ 79.4 million |  |  |

- (1) This revenue guidance was given in relation to the revenue without wafer shipments from Wuhan Xinxin in 4Q13.
- (2) Exclude the effect of foreign exchange, funding of R&D contracts from the government, gain arising from the disposal of living quarters and employee bonus accrual



# Capital Expenditures & Depreciation

| (US\$ millions)                   | 1Q13 | 2Q13 | 3Q13 | 4Q13 | 1Q14 |
|-----------------------------------|------|------|------|------|------|
| Capex                             | 185  | 302  | 169  | 114  | 108  |
| Depreciation<br>&<br>Amortization | 136  | 136  | 137  | 139  | 137  |



## Thank you

Contact us: ir@smics.com